N
152.65
0.69 (0.45%)
| Previous Close | 151.96 |
| Open | 152.00 |
| Volume | 192,434 |
| Avg. Volume (3M) | 954,719 |
| Market Cap | 15,219,576,832 |
| Price / Earnings (TTM) | 36.43 |
| Price / Earnings (Forward) | 21.28 |
| Price / Sales | 5.80 |
| Price / Book | 5.05 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
0.7
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.70 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 203.00 (Citigroup, 32.99%) | Buy |
| Median | 179.00 (17.27%) | |
| Low | 160.00 (RBC Capital, 4.82%) | Buy |
| Average | 181.09 (18.64%) | |
| Total | 11 Buy | |
| Avg. Price @ Call | 140.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 05 Dec 2025 | 200.00 (31.02%) | Buy | 152.65 |
| Morgan Stanley | 11 Nov 2025 | 173.00 (13.33%) | Buy | 147.29 |
| 20 Oct 2025 | 168.00 (10.06%) | Buy | 141.33 | |
| JP Morgan | 03 Nov 2025 | 179.00 (17.27%) | Buy | 141.96 |
| Truist Securities | 30 Oct 2025 | 172.00 (12.68%) | Buy | 138.04 |
| Canaccord Genuity | 29 Oct 2025 | 164.00 (7.44%) | Buy | 138.02 |
| Citigroup | 29 Oct 2025 | 203.00 (32.99%) | Buy | 138.02 |
| 21 Oct 2025 | 175.00 (14.65%) | Buy | 142.65 | |
| Needham | 29 Oct 2025 | 184.00 (20.54%) | Buy | 138.02 |
| 22 Sep 2025 | 170.00 (11.37%) | Buy | 146.62 | |
| Piper Sandler | 29 Oct 2025 | 179.00 (17.27%) | Buy | 138.02 |
| RBC Capital | 29 Oct 2025 | 160.00 (4.82%) | Buy | 138.02 |
| Stifel | 29 Oct 2025 | 183.00 (19.89%) | Buy | 138.02 |
| UBS | 09 Oct 2025 | 195.00 (27.75%) | Buy | 138.47 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MORROW GEORGE J | - | 143.53 | -15,000 | -2,152,950 |
| Aggregate Net Quantity | -15,000 | |||
| Aggregate Net Value ($) | -2,152,950 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 143.53 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MORROW GEORGE J | Director | 25 Nov 2025 | Automatic sell (-) | 15,000 | 143.53 | 2,152,950 |
| MORROW GEORGE J | Director | 25 Nov 2025 | Option execute | 15,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |